MCID: RBL001
MIFTS: 64

Rubella

Categories: Eye diseases, Fetal diseases, Infectious diseases, Liver diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 43 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to measles and acute disseminated encephalomyelitis, and has symptoms including fever, conjunctivitis and headache. An important gene associated with Rubella is MOG (Myelin Oligodendrocyte Glycoprotein), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and eye, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 76 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 measles 32.7 DDX58 IFNAR2 IL4
2 acute disseminated encephalomyelitis 32.2 HLA-B HLA-DQB1 HLA-DRB1 IL10 MOG
3 mumps 31.8 HLA-DPB1 HLA-DRB1 IFNAR2 IL10RB IL12RB2 TNF
4 tetanus 30.4 CD40LG IL10 IL4
5 arthritis 30.4 HLA-DQB1 HLA-DRB1 IL10 TNF
6 myelitis 30.3 HLA-DPB1 MOG TNF
7 cytomegalovirus infection 30.3 HLA-A HLA-B TNF
8 anterior uveitis 30.2 HLA-A HLA-B TNF
9 uveitis 30.2 HLA-B IL10 IL4 TNF
10 poliomyelitis 30.2 IL10 IL4 TNF
11 toxoplasmosis 30.2 CD40LG HLA-DQB1 IL10 IL4 TNF
12 juvenile rheumatoid arthritis 30.2 HLA-DPB1 HLA-DRB1 TNF
13 viral infectious disease 30.2 CD40LG DDX58 IL10 IL4 TNF
14 optic neuritis 30.1 HLA-DRB1 MOG TNF
15 pneumonia 30.1 CD40LG IL10 TNF
16 diabetes mellitus 30.1 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
17 neuritis 30.0 IL4 MOG TNF
18 herpes zoster 30.0 HLA-A HLA-B IL10
19 chlamydia 29.9 IL10 IL4 TNF
20 multiple sclerosis 29.7 HLA-DQB1 HLA-DRB1 IL10 IL4 MOG TNF
21 recurrent respiratory papillomatosis 29.7 HLA-DQB1 HLA-DRB1
22 intermediate uveitis 29.7 HLA-B IL10 TNF
23 rheumatic fever 29.7 HLA-DRB1 IL10 TNF
24 vasculitis 29.6 CD40LG HLA-B TNF
25 myocarditis 29.6 CD40LG HLA-B HLA-DQB1 TNF
26 rheumatoid arthritis 29.5 CD40LG HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
27 human immunodeficiency virus infectious disease 29.5 IL10 TNF TRIM5
28 asthma 29.5 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL4
29 hematopoietic stem cell transplantation 29.5 HLA-A HLA-B IL10 TNF
30 panuveitis 29.4 HLA-A HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
31 rheumatic disease 29.4 CD40LG HLA-B HLA-DRB1 IL10 TNF
32 malaria 29.2 CD40LG HLA-A HLA-B HLA-DRB1 IL10 IL4
33 human immunodeficiency virus type 1 29.2 HLA-A HLA-B IL10 TNF TRIM5
34 autoimmune disease 29.1 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 IL4
35 inflammatory bowel disease 28.8 HLA-B HLA-DQB1 HLA-DRB1 IL10 IL10RB IL12RB2
36 congenital rubella 12.8
37 rubella panencephalitis 12.2
38 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 12.0
39 congenital toxoplasmosis 11.3
40 microcephaly 11.1
41 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
42 immunodeficiency 45 11.0
43 congenital intrauterine infection-like syndrome 11.0
44 togaviridae disease 11.0
45 torch syndrome 11.0
46 immune-mediated encephalomyelitis 11.0
47 postinfectious encephalomyelitis 11.0
48 hepatitis 10.4
49 chickenpox 10.3
50 autism 10.3

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12
  • fever
  • conjunctivitis
  • headache
  • lymphadenopathy
  • joint pains
  • rash on the face which spreads to the trunk

UMLS symptoms related to Rubella:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Rubella:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 C1QBP CALR CD40LG DDX58 HLA-DQB1 IL10
2 hematopoietic system MP:0005397 9.9 C1QBP CD40LG DDX58 HLA-DQB1 IFNAR2 IL10
3 digestive/alimentary MP:0005381 9.8 DDX58 HLA-DQB1 IL10 IL10RB IL12RB2 IL4
4 immune system MP:0005387 9.65 CD40LG DDX58 HLA-DQB1 IFNAR2 IL10 IL10RB
5 liver/biliary system MP:0005370 9.17 DDX58 HLA-DQB1 IL10 IL10RB IL12RB2 IL4

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Liver Extracts Phase 4
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
8
Tetracycline Approved, Vet_approved Phase 3,Phase 1,Phase 2 60-54-8 5353990
9
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
10
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
11
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
13
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
14
Cobalamin Experimental Phase 3 13408-78-1 6438156
15 Hemagglutinins Phase 3
16 taxane Phase 3
17 Somatomedin B Phase 3
18 Anti-Infective Agents Phase 3,Phase 1,Phase 2
19 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
20 Vitamin B 12 Phase 3
21 Vitamin B12 Phase 3
22 PENTA Phase 3,Phase 2
23 Retinol palmitate Phase 3
24 Antioxidants Phase 3
25 Micronutrients Phase 3
26 Protective Agents Phase 3,Phase 2
27 retinol Phase 3
28 Trace Elements Phase 3
29 Vitamins Phase 3
30
Altretamine Approved Phase 2 645-05-6 2123
31
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
35
Mycophenolic acid Approved Phase 2 24280-93-1 446541
36
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
37
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
38
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
39
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
40 Anticoagulants Phase 2
41 Fibrinolytic Agents Phase 2
42 Proteasome Inhibitors Phase 2
43 Hormone Antagonists Phase 2
44 Antineoplastic Agents, Hormonal Phase 2
45 Prednisolone acetate Phase 2
46 Antiemetics Phase 2
47 Methylprednisolone acetate Phase 2
48 Neuroprotective Agents Phase 2
49 Anti-Inflammatory Agents Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Unknown status NCT01770119 Phase 4
3 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
4 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
5 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
6 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
7 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
8 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
9 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
10 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
11 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
12 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
13 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
14 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
15 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
16 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
17 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
18 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
19 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
20 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
21 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
22 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
23 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
24 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
25 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
26 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
27 MMR at 6 Months Trial Not yet recruiting NCT03780179 Phase 4
28 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
29 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
30 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
31 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
32 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
33 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
34 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
35 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
36 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
37 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
38 Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III) Completed NCT03713359 Phase 3
39 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
40 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
41 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
42 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
43 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
44 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
45 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
46 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
47 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
48 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
49 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
50 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

19
Skin

MalaCards organs/tissues related to Rubella:

41
Heart, Eye, Skin, Brain, Lymph Node, Liver, Testes

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 2002)
# Title Authors Year
1
Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: The success of a vaccination program. ( 30454948 )
2019
2
Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. ( 30503658 )
2019
3
Adverse pregnancy outcomes among pregnant women with acute Rubella infections in Mwanza city, Tanzania. ( 30391418 )
2019
4
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy. ( 29411259 )
2018
5
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
6
Rubella viruses shift cellular bioenergetics to a more oxidative and glycolytic phenotype with a strain-specific requirement for glutamine. ( 29950419 )
2018
7
Multimodal imaging in serologically confirmed Rubella retinopathy. ( 29934649 )
2018
8
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. ( 29943738 )
2018
9
Towards rubella elimination in Japan. ( 29976516 )
2018
10
Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016. ( 29766840 )
2018
11
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
12
Decreased antibodies against rubella in previously vaccinated treatment-naA^ve childhood systemic lupus erythematous patients: a prospective case-control study. ( 29741129 )
2018
13
Rubella natural immunity among adolescent girls in Tanzania: the need to vaccinate child bearing aged women. ( 29298693 )
2018
14
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
15
Congenital rubella syndrome: A brief review of public health perspectives. ( 29512566 )
2018
16
Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro. ( 29300335 )
2018
17
Parallel Evolution of Common Allelic Variants Confers Flowering Diversity in <i>Capsella rubella</i>. ( 29764984 )
2018
18
An Intraocular Inflammatory Profile of Rubella Associated Uveitis. ( 29370571 )
2018
19
Imported Congenital Rubella Syndrome, United States, 2017. ( 29553333 )
2018
20
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
21
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
22
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
23
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
24
Progress Toward Rubella and Congenital Rubella Syndrome Control - South-East Asia Region, 2000-2016. ( 29851943 )
2018
25
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
26
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
27
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
28
Seroprevalence of HIV, HTLV, CMV, HBV and rubella virus infections in pregnant adolescents who received care in the city of BelAcm, ParA!, Northern Brazil. ( 29769062 )
2018
29
Response to third rubella vaccine dose. ( 29771601 )
2018
30
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. ( 29865869 )
2018
31
Congenital Rubella ( 29939656 )
2018
32
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. ( 29975677 )
2018
33
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
34
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. ( 29965975 )
2018
35
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
36
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
37
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018
38
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
39
Two Imported Cases of Congenital Rubella Syndrome and Infection-Control Challenges in New York State, 2013-2015. ( 28510706 )
2018
40
Congenital rubella syndrome surveillance in South Africa using a sentinel site approach: a cross-sectional study. ( 30203002 )
2018
41
Sentinel Surveillance for Congenital Rubella Syndrome - India, 2016-2017. ( 30212443 )
2018
42
The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries. ( 30285537 )
2018
43
Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic review of existing literature and transmission modelling of sero-prevalence studies. ( 30289078 )
2018
44
Hospital based surveillance of congenital rubella syndrome cases in the pre-vaccine era in Amhara Regional State, Ethiopia: A base line information for the country. ( 30419036 )
2018
45
Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. ( 29454516 )
2018
46
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. ( 29576304 )
2018
47
Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing. ( 30158679 )
2018
48
Acute Encephalitis with Atypical Presentation of Rubella in Family Cluster, India. ( 30226166 )
2018
49
Seroprevalence data at a private teaching hospital in Kenya: An examination of Toxoplasma gondii, cytomegalovirus, rubella, hepatitis A, and Entamoeba histolytica. ( 30325924 )
2018
50
Active immunization status against measles, mumps, rubella, hepatitis B in internationally adopted children, surveyed at the university hospital of Palermo, Sicily. ( 30062371 )
2018

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CALR CD40LG DDX58 HLA-A HLA-B HLA-DPB1
2
Show member pathways
13.4 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
3
Show member pathways
13.04 CALR DDX58 HLA-A HLA-B IFNAR2 IL10RB
4
Show member pathways
12.94 CD40LG DDX58 HLA-A HLA-B HLA-DPB1 HLA-DQB1
5
Show member pathways
12.71 C1QBP DDX58 HLA-A HLA-B HLA-DPB1 HLA-DQB1
6
Show member pathways
12.6 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB IL12RB2
7 12.58 C1QBP CD40LG DDX58 IL10 IL4 TNF
8
Show member pathways
12.51 HLA-A HLA-B IFNAR2 IL4 TNF
9
Show member pathways
12.51 DDX58 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
10
Show member pathways
12.51 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNAR2 IL10
11 12.43 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
12
Show member pathways
12.39 IFNAR2 IL10 IL10RB IL12RB2 IL4
13
Show member pathways
12.38 CD40LG IL10 IL4 TNF
14
Show member pathways
12.28 HLA-A HLA-B IFNAR2 IL10 IL4 TNF
15
Show member pathways
12.28 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB
16 12.25 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB TNF
17
Show member pathways
12.18 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
18 12.17 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
19 12.13 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
20 12.11 CALR DDX58 HLA-A HLA-B HLA-DPB1 HLA-DQB1
21
Show member pathways
11.98 HLA-A HLA-DRB1 IL12RB2 IL4
22 11.93 IL10 IL4 TNF
23 11.93 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL4 TNF
24 11.92 IL10 IL4 TNF
25
Show member pathways
11.9 HLA-DPB1 HLA-DQB1 HLA-DRB1
26 11.88 IFNAR2 IL10 IL10RB IL12RB2
27 11.87 HLA-DPB1 HLA-DQB1 HLA-DRB1
28 11.86 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
29 11.83 CD40LG DDX58 TNF
30 11.8 IL10 IL12RB2 IL4 TNF
31
Show member pathways
11.73 CD40LG IL4 TNF
32 11.69 IL10 IL4 TNF
33 11.64 CD40LG IL10 IL4
34 11.63 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
35
Show member pathways
11.62 HLA-A IFNAR2 TNF
36 11.56 IL10 IL10RB IL4 TNF
37 11.52 CD40LG IL10 TNF
38 11.49 IL10 IL12RB2 IL4
39 11.36 IL10 IL10RB TNF
40 11.3 HLA-DRB1 IL10 IL4 TNF
41 11.19 CD40LG IL10 IL4 TNF
42 11.19 CALR HLA-A HLA-B
43
Show member pathways
11.15 DDX58 IFNAR2 IL10RB

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.92 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
2 cell surface GO:0009986 9.76 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
3 external side of plasma membrane GO:0009897 9.73 CALR CD40LG HLA-DRB1 IL12RB2 MOG TNF
4 trans-Golgi network membrane GO:0032588 9.69 HLA-DPB1 HLA-DQB1 HLA-DRB1
5 phagocytic vesicle membrane GO:0030670 9.65 CALR HLA-A HLA-B
6 endocytic vesicle membrane GO:0030666 9.63 HLA-DPB1 HLA-DQB1 HLA-DRB1
7 transport vesicle membrane GO:0030658 9.61 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DPB1 HLA-DQB1 HLA-DRB1
9 MHC class II protein complex GO:0042613 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
10 MHC class I protein complex GO:0042612 9.49 HLA-A HLA-B
11 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
13 membrane GO:0016020 10.38 C1QBP CALR CD40LG DDX58 HLA-A HLA-B
14 plasma membrane GO:0005886 10.22 C1QBP CD40LG DDX58 HLA-A HLA-B HLA-DPB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 C1QBP DDX58 HLA-A HLA-B HLA-DPB1 HLA-DRB1
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 CD40LG TNF TRIM22 TRIM5
3 regulation of immune response GO:0050776 9.88 CD40LG HLA-A HLA-B IL4 MOG
4 viral process GO:0016032 9.87 C1QBP DDX58 HLA-B HLA-DRB1 MOG TRIM22
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.85 HLA-DPB1 HLA-DQB1 HLA-DRB1
6 T cell receptor signaling pathway GO:0050852 9.85 HLA-DPB1 HLA-DQB1 HLA-DRB1 MOG
7 defense response to virus GO:0051607 9.85 DDX58 IFNAR2 IL10RB TRIM22 TRIM5
8 cytokine-mediated signaling pathway GO:0019221 9.85 IFNAR2 IL10 IL10RB IL12RB2 IL4 TNF
9 response to organic substance GO:0010033 9.84 CALR IL10 TNF
10 B cell differentiation GO:0030183 9.83 CD40LG IL10 IL4
11 type I interferon signaling pathway GO:0060337 9.82 HLA-A HLA-B IFNAR2
12 response to virus GO:0009615 9.81 DDX58 IFNAR2 TNF TRIM22
13 positive regulation of T cell proliferation GO:0042102 9.8 CD40LG HLA-DPB1 IL4
14 positive regulation of interferon-gamma production GO:0032729 9.77 HLA-DPB1 IL12RB2 TNF
15 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.71 CALR HLA-A HLA-B
16 negative regulation of interferon-gamma production GO:0032689 9.7 C1QBP HLA-DRB1 IL10
17 negative regulation of growth of symbiont in host GO:0044130 9.68 IL10 TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
19 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.67 CALR HLA-A HLA-B
20 negative regulation of interleukin-12 production GO:0032695 9.66 C1QBP IL10
21 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.66 HLA-A HLA-B
22 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
23 positive regulation of DNA-binding transcription factor activity GO:0051091 9.65 DDX58 IL10 TNF TRIM22 TRIM5
24 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.64 HLA-A HLA-B
25 positive regulation of dendritic cell chemotaxis GO:2000510 9.64 C1QBP CALR
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
28 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.62 HLA-DQB1 HLA-DRB1
29 protection from natural killer cell mediated cytotoxicity GO:0042270 9.61 HLA-A HLA-B
30 regulation of immunoglobulin secretion GO:0051023 9.61 CD40LG TNF
31 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.61 HLA-DPB1 HLA-DQB1 HLA-DRB1
32 regulation of isotype switching GO:0045191 9.59 IL10 IL4
33 type 2 immune response GO:0042092 9.58 IL10 IL4
34 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.57 HLA-DQB1 HLA-DRB1
35 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
36 antigen processing and presentation GO:0019882 9.55 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
37 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TRIM22
38 immune response GO:0006955 9.4 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.26 CD40LG IL10 IL4 TNF
3 complement component C1q binding GO:0001849 9.16 C1QBP CALR
4 peptide antigen binding GO:0042605 9.02 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....